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The aim of the present study was to assess the frequency of human herpesvirus 6A 
(HHV-6A) and human herpesvirus 6B (HHV-6B) infection during pregnancy. 100-100 blood 
samples were collected from pregnant and non pregnant women, then nucleic acid was 
isolated from both plasma and leukocytes fraction. Nested and real-time PCR were used to 
detect and differentiate HHV-6A and HHV-6B DNA and to determine viral loads. Reverse 
transcription PCR (RT-PCR) for HHV-6 U79/80 mRNA was performed in order to reveal 
active HHV-6 replication.  
HHV-6A and HHV-6B active infection was not detected in blood samples neither 
from pregnant nor from non pregnant women. Frequency of HHV-6B and HHV-6A latency 
did not show difference between the studied groups (15 % vs. 16%). HHV-6B latency was 
dominant in both studied groups (14/15 and 15/16). Beside these results, in leukocyte samples 
of one pregnant and three non pregnant women high HHV-6A viral loads (1.28 X 10
5 
- 5.07 X 
10
5
 GEq / 1.5 X 10
6
 leukocytes) were detected, and viral DNA was also found in plasma 
samples. Although RT-PCR did not confirm virus replication, but chromosomal integration 
was also not proved unequivocally, the number of 0.08-0.33 HHV-6 copy/ 1 leukocyte refers 
more to postnatal infection.  
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Introduction 
 Human herpesvirus 6A and 6B were classified as distinct viruses in 2012 by the 
International Committee on Taxonomy of Viruses [1]. Based on seroepidemiologic studies 
seropositivity in adult population exceeds 95 %, however it is important to note that most of 
these studies did not discriminate HHV-6A and HHV-6B [2]. Spreading via saliva is 
suggested as the most probable way of horizontal transmission [3], but vertical, transplacental 
transmission of maternal infections (primary infection or reactivation) is also possible, the 
frequency is about 1 % [4-7]. Chromosomal integration of HHV-6A and HHV-6B (ciHHV6) 
in germ line also enables the vertical transmission via a Mendelian manner, the frequency is 
0.2-2 % [8]. Although HHV-6A or HHV-6B can be detected in the genital tract of a fifth of 
pregnant women, perinatal transmission is suggested to be unlikely [9, 10]. 
Primary infection occurs in children between 6 months and 2 years, almost exclusively 
with HHV-6B, after which latency is established [11]. Specific clinical symptoms are not 
realised in most of the cases, but exanthema subitum is a characteristic disease in 1/3 of the 
infections [2]. Little is known about HHV-6A infection. It may cause symptomatic, even 
primary [12] infection in children, but it is also suggested that asymptomatic HHV-6A 
infection may occur after the HHV-6B childhood infection, later in life [2]. Reactivation of 
latent HHV-6B and HHV-6A may occur in mostly immunocompromised patients and rarely 
in immunocompetent individuals [8]. Transient immunosuppression during pregnancy may 
result in reactivation of latent infections or may result in higher susceptibility to infections. 
Seroprevalence studies revealed that the rate of HHV-6 seropositivity in pregnant and non 
pregnant women are not different and 97-100 %, but the antibody titer is significantly lower 
in pregnant women, and low avidity IgG was detected in 5 % of  pregnant women [13, 14]. 
Since only some publications are available about HHV-6 infection during pregnancy, and no 
data is published from Hungary, the aim of this study was to determine the prevalence of 
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HHV-6A and HHV-6B in peripheral blood from pregnant and non pregnant women in 
Hungary, to study whether active infection occurs during pregnancy. 
 
Materials and methods 
Study groups and samples 
 EDTA blood samples were collected from 100 healthy pregnant (age 16.5–41.9 years, 
median 32.1 years) women. 28 of them were in the first trimester, 27 in the second, and 45 in 
the third trimester of pregnancy. As control, EDTA blood samples were collected from 
healthy, non pregnant women (age 18–44.3 years, median 31.6 years). Regional and 
Institutional Ethics Committee of University of Debrecen approved the study. 
Nucleic acid was isolated immediately after blood taken from samples using High 
Pure Viral Nucleic Acid Kit (Roche, Switzerland) according to the manufacturer’s 
instructions. Plasma fraction was obtained from EDTA blood sample after centrifugation, then 
200 µL plasma was used for nucleic acid isolation. Red blood cells from the cell pellet were 
lysed with sterile, nuclease free lysis buffer containing ammonium chloride, potassium 
carbonate and EDTA. Leukocytes (white blood cells, WBCs) were washed with sterile, 
nuclease free phosphate buffered saline, then nucleic acid was isolated from 1.5 X 10
6
 WBCs. 
Nucleic acids were stored at −20 °C until use. 
 
Detection of HHV-6A and HHV-6B DNA in samples 
 Nested HHV-6 PCR which able to differentiate HHV-6A and HHV-6B based on the 
size of the PCR amplicons was performed as described previously [15]. Quantitative HHV-6 
real-time PCR (Q-PCR) was carried out with HHV6 ELITe MGB® Kit (ELITech Group, 
France) using 7500 Real-Time PCR System (Applied Biosystems, USA) according to the 
instructions. The multiplex real-time kit ensures detection of human beta globin gene beside 
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the HHV-6 U67, hence effectiveness of nucleic acid isolation was also tested. Chi sqare test 
and Fisher's exact test were used to asses the difference in frequency for categorical variables. 
Difference was considered significant if p<0.05. 
 
HHV-6 reverse transcription-PCR (RT-PCR) 
 To synthesize cDNA High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, USA) with random hexamers were used after DNaseI treatment of nucleic acid 
isolated from WBCs (Sigma-Aldrich, USA). To control the effectiveness of RNA isolation, 
GAPDH RT-PCR was carried out as detailed previously [16]. HHV-6 RT-PCR was 
performed as described previously [15]. 
 
Results 
 HHV-6B was detected in 14 WBC samples from pregnant women and 15 WBC 
samples from non pregnant women (14/100 vs. 15/100; p>0.05), while HHV-6A was revealed 
in WBCs from one pregnant and one non pregnant woman (1/100 vs. 1/100). The leukocytes 
from this non pregnant woman carried both HHV-6A and HHV-6B DNA. Viral DNA was 
detected in WBCs with nested PCR, but HHV-6 DNA was found using real-time PCR only in 
four control WBC samples with less than 10 genome equivalent (GEq) per reaction (Table I). 
All the plasma samples from these patients were negative for HHV-6B and HHV-6A DNA, 
suggesting that HHV-6B and HHV-6A latency was detected. 
 One plasma sample from a 35 week pregnant woman was positive for HHV-6A DNA, 
the viral load was 2 X 10
2
 GEq / mL plasma. HHV-6A DNA with 5.07 X 10
5
 GEq / 1.5 X 10
6
 
WBCs viral load was detected also in the leukocytes (Table II.). HHV-6 RT-PCR was 
negative, but GAPDH RT-PCR proved that RNA isolation was successful. HHV-6A DNA 
was detected by nested PCR in plasma samples from four non pregnant women, and in 
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leukocytes from three of them. In plasma sample with HHV-6 negative WBCs Q-PCR did not 
detect viral DNA. The viral loads are detailed in Table II. HHV-6 RT PCR did not prove 
active HHV-6 infection, GAPDH RT-PCR confirmed the presence of amplificable RNA, all 
the samples were positive for GAPDH RNA. 
 
Discussion 
 The present study examined HHV-6A and HHV-6B prevalence in peripheral blood 
from pregnant and non pregnant women. HHV-6B and HHV-6A positivity in leukocytes 
referring to latency was found both in pregnant and non pregnant women; the prevalence did 
not show difference between the two groups (15/100 vs. 16/100). HHV-6B past infection was 
dominant in both pregnant (14/15) and non pregnant (15/16) study group. Latency was found 
in all three trimesters. One pregnant woman carried latent HHV-6A and HHV-6B DNA 
together in her peripheral leukocytes. Our data strengthen the suggestion that primary 
infections occur mainly with HHV-6B [2]. The frequency of DNA positivity found in 
peripheral blood samples depends on the methods used [4, 11, 17]. The sensitivity of the 
nested PCR used in this study was better then the Q-PCR. The commercially available kit 
validated for clinical diagnosis and used in this study found only 4 samples to be positive for 
latent HHV-6 DNA, even the sensitivity of the Q-PCR is 10 GEq / PCR.  
 HHV-6A DNA in plasma was detected by nested PCR in samples from pregnant 
(2/100) and non pregnant women (4/100), the difference is not significant statistically. In one 
pregnant woman HHV-6 DNA was found only in plasma and not in WBCs, and the viral load 
was less then the sensitivity of the Q-PCR. In that case HHV-6 might replicate in other tissue 
and not in blood. HHV-6B in plasma samples was not detected. HHV-6 RT PCR did not 
prove active HHV-6 replication, since HHV-6 U79/80 mRNA could not be detected.  Beta 
globin DNA, hence the release of genomic DNA from dead cells was detected in nucleic acids 
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isolated from plasma using HHV6 ELITe MGB® Kit. Not any of these patients had clinical 
symptoms. We have no data about the previous HHV-6 serostatus of the patients.  It cannot be 
excluded whether any of the studied patients have ciHHV-6, but Q-PCR did not confirm it. 
Despite the HHV-6 viral loads in plasma were 2.03 X 10
2
 - 2.5 X 10
3
 GEq / mL plasma, RT-
PCR did not prove active HHV-6 infection. Presence of genomic DNA from dead cells was 
revealed suggesting that HHV-6 DNA might be released from cells. In patients with ciHHV-6 
HHV-6 genome exists in all nucleated cell, the ratio of viral genome to human genome is 1:1 
[8]. Although HHV-6 viral loads in WBC samples were high in these patients, the HHV-6 
copy number / 1 leukocyte did not prove ciHHV-6 (0.08-0.33 GEq/ 1 leukocyte) 
unequivocally, hence postnatal infections are most likely [8, 18]. Infection or reactivation 
shortly before the sample taken cannot be excluded. Since the sample from a pregnant woman 
was collected in the 35
th
 week of pregnancy, it might occur during pregnancy. Reactivation of 
latent infection during pregnancy might be transmitted through the placenta, but antibodies 
against the known virus might prevent congenital infections. At the same time, antibody from 
previous HHV-6B or HHV-6A infection might not prevent from reinfection with the other 
HHV-6 virus or from different genotypes [13].  
In conclusion, active HHV-6A or HHV-6B infection was not detected during 
pregnancy. Frequency of HHV-6B and HHV-6A latency did not show difference between 
pregnant and non pregnant study group, HHV-6B virus was found to be dominant. In blood 
samples from one pregnant woman and three non pregnant women high viral loads of HHV-
6A were found, RT-PCR did not confirm active HHV-6 replication. The result of the Q-PCR 
refers more to postnatal infection then ciHHV-6.  
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